Cardiotoxicity of 5-fluorouracil in a young colorectal cancer patient - case report and review of literature

Pyrimidine analogues such as 5-fluorouracil (5-FU) are widely used in adjuvant and palliative treatment of various solid tumours. However, their administration may be associated with severe adverse events such as myelosuppression, mucositis or cardiotoxicity. Cardiotoxicity is a relatively rare even...

Full description

Saved in:
Bibliographic Details
Published in:Archives of medical science 2009-07, Vol.5 (2), p.277
Main Authors: Wysocki, Piotr J, Hutka, Malgorzata
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pyrimidine analogues such as 5-fluorouracil (5-FU) are widely used in adjuvant and palliative treatment of various solid tumours. However, their administration may be associated with severe adverse events such as myelosuppression, mucositis or cardiotoxicity. Cardiotoxicity is a relatively rare event but its fatal outcomes occur at a rate of 2.2-13.3%. Since 5-fluorouracil is widely used in medical oncology, cardiotoxicity associated with its administration may significantly impair treatment of patients with cancers sensitive to pyrimidine analogues. This article reviews fluoropyrimidine-associated cardiotoxicity and presents a case report of a young woman who experienced this complication during 5-fluorouracil treatment.
ISSN:1734-1922
1896-9151